There are currently 815 clinical trials in Washington, District Of Columbia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's National Medical Center, Medstar Georgetown University Hospital, MedStar Washington Hospital Center and Walter Reed Army Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Massage Impact on Sleep in Pediatric Oncology
NCT06892158
Recruiting
This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/18/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
NCT05907629
Recruiting
CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPT... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
Implementing a Scalable Smoke-free Home Intervention in Armenia and Georgia
NCT06166433
Recruiting
Tobacco use and secondhand smoke exposure represent critical health disparities in low- and middle-income countries; Armenia and Georgia represent the 11th and 6th highest smoking rates in men globally (51.5% and 55.5%, respectively), but have low rates of smoking in women (1.8% and 7.8%) and few smoke-free homes (38.6%), which can reduce secondhand smoke exposure and tobacco use rates. This study builds on ongoing collaborations between George Washington University, Emory, and national public h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: George Washington University, Washington, District of Columbia
Conditions: Second Hand Tobacco Smoke
Register for Updates
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
NCT06248515
Recruiting
The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Conditions: Thymoma, Thymic Carcinoma
Register for Updates
Leveraging Telehealth to Improve Oral Health Among Cancer Survivors
NCT06315855
Recruiting
The investigators will conduct a 2-arm 6-month randomized clinical controlled trial to evaluate the effectiveness of an oral Telehealth Intervention (THI) in preventing cancer-related oral complications, improving oral health maintenance and oral health related quality of life, and reducing systemic inflammation compared to Usual Care (UC) among unselected cancer survivors.
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
03/11/2025
Locations: Georgetown Lombardi Office of Minority Health, Washington, District of Columbia
Conditions: Oral Mucositis, Periodontal Diseases, Cancer
Register for Updates
Older Breast Cancer Patients: Risk for Cognitive Decline
NCT03451383
Recruiting
The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hosp... Read More
Gender:
FEMALE
Ages:
Between 60 years and 105 years
Trial Updated:
03/10/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Cancer, Breast, Age-related Cognitive Decline, Cognitive Decline
Register for Updates
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
NCT04972942
Recruiting
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoin... Read More
Gender:
ALL
Ages:
39 years and below
Trial Updated:
03/10/2025
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Register for Updates
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT05334732
Recruiting
The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Medstar Georgetown University Hospital, Washington, District of Columbia
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Meridian Clinical Research, Washington, District of Columbia
Conditions: SARS-CoV-2
Register for Updates
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697
Recruiting
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: George Washington University, Washington, District of Columbia
Conditions: Advanced Solid Tumors
Register for Updates
Peer Behavioral Activation Utilization to Address Structural Racism and Discrimination and Improve HIV Outcomes in High-Risk, Substance-Using Populations
NCT06501781
Recruiting
This randomized Type 1 hybrid effectiveness-implementation trial (N=186) will evaluate the effectiveness and implementation of a peer-delivered problem solving and behavioral activation intervention for adherence to LAI-PrEP/ART ("Peer Activate-LAI") compared to enhanced treatment as usual (ETAU) for a largely Black, substance-using population living with or at high risk for HIV. Specific aims are to: Aim 1: Evaluate the effectiveness of Peer Activate-LAI over 12-months on: a) LAI-PrEP/ART adhe... Read More
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
03/07/2025
Locations: HIPS (Harm reduction drop-in center), Washington, District of Columbia
Conditions: HIV Infections, Substance Use
Register for Updates